1630 Full

BRIEF REVIEW
www.jasn.org
Assessment and Management of Hypertension in

Patients on Dialysis
Rajiv Agarwal,* Joseph Flynn, Velvie Pogue, Mahboob Rahman, Efrain Reisin,| and
Matthew R. Weir
*Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush
Veterans Affairs Medical Center, Indianapolis, Indiana; Division of Nephrology, Seattle Childrens Hospital, University of
Washington, Seattle, Washington; formerly Division of Nephrology, Harlem Hospital, Columbia University College of
Physicians & Surgeons, New York, New York; Division of Nephrology and Hypertension, University Hospitals Case
Medical Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Case Western Reserve University, Cleveland,
Ohio; |Division of Nephrology and Hypertension, Louisiana State University Health Science Center, New Orleans,
Louisiana; and Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore,
Maryland
ABSTRACT
Hypertension is common, difcult to diagnose, and poorly controlled among
patients with ESRD. However, controversy surrounds the diagnosis and treatment
of hypertension. Here, we describe the diagnosis, epidemiology, and management
of hypertension in dialysis patients, and examine the data sparking debate over
appropriate methods for diagnosing and treating hypertension. Furthermore, we
consider the issues uniquely related to hypertension in pediatric dialysis patients.
Future clinical trials designed to clarify the controversial results discussed here
should lead to the implementation of diagnostic and therapeutic techniques that
improve long-term cardiovascular outcomes in patients with ESRD.
J Am Soc Nephrol 25: 16301646, 2014. doi: 10.1681/ASN.2013060601
Hypertension is common among patients with ESRD. In this review, we

discuss the diagnosis, epidemiology, and
management of hypertension among
dialysis patients. We also review areas
of existing controversies and briey
discuss the issue of hypertension in
pediatric dialysis patients.
EPIDEMIOLOGY
The prevalence, treatment, and control

of hypertension among people on hemodialysis (HD) have used varying
denitions to diagnose hypertension.
The epidemiology differs based on
how BP is measured: either before and
after dialysis or using ambulatory BP
recordings.
1630
ISSN : 1046-6673/2508-1630
Epidemiology with Routine BP

Measurements
The prevalence of hypertension (dened

as 1-week average predialysis systolic BP
[SBP] measurements .150 mmHg or diastolic BP [DBP].85 mmHg or the use of
antihypertensive medications) was 86%
among 2535 clinically stable adult HD patients participating in a multicenter trial.1
Among hypertensive patients, 12% did
not receive antihypertensive drugs, 58%
were treated but not controlled, and only
30% were controlled. The use of antihypertensive drugs has been reported to vary
from 59% to 83%.25 Furthermore, even
among children on long-term HD, similar
ndings have been reported.6 Several
studies have conrmed greater antihypertensive drug use to be associated with
poorer control.7,8 It should be noted that
antihypertensive drug use per se do not

lead to worse BP control; in the absence
of adequate volume control, increasing
antihypertensive drug use may simply reect difcult-to-control BP.
Epidemiology Using Ambulatory BP
Measurements
The prevalence of hypertension (dened

by either a 44-hour interdialytic ambulatory BP of $135/85 mmHg or the prescription of any antihypertensive agent)
was 86% among 369 chronic HD patients.8 Although hypertension was being
treated with antihypertensive drugs in
89% of patients, it was adequately controlled only in 38%. The independent determinants of poor control were the use of
antihypertensive drugs and an expanded
extracellular volume state. If patients were
volume overloaded, nearly 80% became
hypertensive when medications were
Published online ahead of print. Publication date

available at www.jasn.org.
Correspondence: Dr. Rajiv Agarwal, Division of
Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L.
Roudebush Veterans Affairs Medical Center, 1481
West 10th Street, 111N, Indianapolis, IN 46202.
Email: ragarwal@iupui.edu
Copyright 2014 by the American Society of
Nephrology
J Am Soc Nephrol 25: 16301646, 2014
www.jasn.org
withdrawn. Paradoxically, the more medications the patients received, the more
likely they were to be hypertensive.
Epidemiology of Hypertension in
Peritoneal Dialysis
Some studies suggest that hypertension

control in patients on peritoneal dialysis
(PD) is superior compared with those on
HD.9,10 For example, among 1202 patients participating in the 1995 Peritoneal Dialysis Core Indicators Study, the
average BP among PD patients was 139/
80 mmHg.11 This is in contrast with the
predialysis BP of 152/82 mmHg among
1238 participants in the Hemodialysis
study 3 or in another study including
414 Italian PD patients, in which the
prevalence of hypertension was 88%
based on ofce BP$140/90 mmHg and
69% based on BP load .30%.12 Some
have theorized that better BP control in
PD patients could be explained in part by
removal of vasopressors and sodium
pump inhibitors by PD.13
In another study, the comparison of
22 patients on HD with 24 patients on PD
with 44-hour ambulatory BP monitoring showed no differences in daytime
and nighttime BP.14 Nonetheless, highquality head-to-head studies are sparse
and the epidemiology of hypertension
may be similar to that seen among HD
patients.15
Among PD patients, volume excess, as
assessed by tracer dilution, was common
and was related to DBP and eccentric left
ventricular hypertrophy (LVH).16 Volume
overload in PD patients may be related to
the peritoneal transport characteristics.17
High transporters tend to have a higher
BP; ultraltration may restore their BP
to more normotensive levels.17 In a small
study, patients on continuous cyclic PD
were reported to have a greater left ventricular mass compared with those on
continuous ambulatory PD.18 This was
thought to be a result of greater volume
overload.18
DIAGNOSIS
The diagnosis of hypertension among

patients on HD is challenging and this
J Am Soc Nephrol 25: 16301646, 2014
may lead to overtreatment or undertreatment of hypertension.1922 Diagnosing

hypertension is difcult for several reasons.23 BP in these patients is often measured without attention to technique.24
BP declines during HD with ultraltration. This decline in BP can be variable
and in part is related to the magnitude
and intensity of ultraltration.25 For example, those patients who have a large
volume removed over a short period of
time may have a large decline in BP.
These patients may also gain the removed
volume back over the interdialytic interval
and have a large increase in BP.26 Predialysis BP may therefore be hypertensive
and postdialysis BP may be hypotensive.
It therefore becomes unclear which BP
measurement to use to diagnose hypertension,27 and substantial errors can occur both in detecting hypertension and
assessing its severity.28,29 Both predialysis
and postdialysis BP measurements are
highly variable such that the variability
between patients is about the same as variability in an individual patient over
time.30 In addition, HD patients have signicant seasonal variability in BP; BP is
highest during winters and lowest during summers.31 This may be related to
temperature-induced vasodilation. Although signicant relationships exist
between both predialysis and postdialysis BP and interdialytic ambulatory
BP,32 a meta-analysis has shown that
predialysis and postdialysis BP measurements agree poorly with interdialytic ambulatory BP. 33 Accordingly,
among HD patients, large errors are
possible when using predialysis or
postdialysis BP to judge the magnitude
of elevation in interdialytic ambulatory
BP.
The existing, although somewhat
dated, National Kidney Foundation Kidney Disease Outcomes Quality Initiative
guidelines recommend that BP measurements should be ,140/90 and ,130/80
mmHg before and after HD, respectively.34 Use of predialysis or postdialysis
BP measurements to make management
decisions in the interdialytic period can
be problematic. For example, in a survey in the United Kingdom, centers
that achieved better postdialysis BP
BRIEF REVIEW
targets had more intradialytic hypotension.35 What is clear is that interdialytic

weight gain increases predialysis BP3,3639
and provokes the use of antihypertensive
therapy. 36,37 However, interdialytic
weight gain does not correlate with interdialytic ambulatory BP.40,41 Therefore,
whether achieving these peridialysis BP
targets would cause clinical harm (or
benet) remains unknown.
Using all BP values measured during a
mid-week dialysis may serve as a more
useful tool to estimate interdialytic ambulatory BP.42 Although the mean intradialytic BP serves as a useful tool to
assess hypertension, the calculation of
median intradialytic BP is computationally easier than calculating the mean. It
may therefore be used as a bedside tool
to predict interdialytic ambulatory BP. A
mid-week median intradialytic BP of
$140/90 mmHg has sensitivity and
specicity that exceeds predialysis or
postdialysis measurements and can serve
as a rapid and convenient tool to assess
hypertension in long-term HD patients.42 However, this is the method of
last resort because better methods are
available to evaluate hypertension in
HD patients.
Home BP monitoring is a practical way
to diagnose and manage hypertension in
all patients with kidney disease.43,44 Home
BP monitoring is recommended by both
the American Heart Association and the
European Society of Hypertension for diagnosing and managing hypertension.45,46
Home BP monitoring is especially valuable in diagnosing and managing hypertension for those on HD for the following
reasons. 47 Home BP correlates more
closely with ambulatory BP compared
with predialysis or postdialysis BP recordings.48 Home BP can track changes in BP
evoked by the reduction in dry weight.49
Home BP, compared with predialysis or
postdialysis BP recordings, is much more
reproducible from one week to the next.49
Home BP is superior to measurements
made in the dialysis unit, even when the
dialysis unit measurements are made using recommended techniques, in predicting the presence of target organ damage
(echocardiographic LVH)50,51 or longterm outcomes such as cardiovascular
Hypertension in ESRD
1631
BRIEF REVIEW
www.jasn.org
events52 or mortality.5255 The association

of BP and outcomes is discussed further in
the section on prognosis. A recent trial
randomized stable HD patients to home
BP-guided therapy or predialysis BPguided therapy.56 The primary goal was
to assess change in interdialytic ambulatory BP at 6 months and change in echocardiographic LVH. There was no change
in ambulatory BP at 6 months in the predialysis BP-guided therapy group. A signicant decrease in ambulatory SBP (but
not DBP) was noted at 6 months in the
group treated using home BP recordings.
Between-group differences were signicant. Given the small number of patients
and variability in timing of echocardiographic left ventricular mass measurements, no between-groups differences
were noted. Another trial randomized 17
HD patients to usual care and 17 patients
to home BP monitoring. Signicant improvement in average weekly SBP was seen
in the home BP group only.57 These data
support the use of home BP measurement
to manage HD patients.
Among HD patients, the timing and
frequency of home BP monitoring is of
particular importance. Home BP increases
on average at a rate of 4 mmHg every 10
hours elapsed after dialysis.58 Therefore,
measurement soon after dialysis or just
before dialysis will underestimate or overestimate the burden of hypertension.
Therefore, it is important to measure BP
at various intervals after dialysis. Simply
obtaining a BP measurement 20 minutes
postdialysis may not yield the most representative interdialytic BP.59 We recommend that measurements be made twice
daily (on waking up in the morning and
just before going to sleep) after a midweek
dialysis for 4 days,60 given that interdialytic BP measures may more capably
predict LVH and mortality.5055 These
measurements allow an adequate number
of measurements for diagnosing and managing hypertension. For long-term followup, monthly measurement (over 4 days
after a midweek dialysis as noted above)
should sufce in most patients. More frequent measurements may be needed in individuals who are clinically unstable.
Ambulatory BP monitoring, among
HD patients, is held to be the gold
1632
standard for diagnosing hypertension.27,6163 Compared with peridialytic

BP recordings, it correlates better with
LVH50 and all-cause mortality.64 While
using a validated monitor, 65 we recommend measuring BP over the entire
interdialytic interval (44 hours). We recommend recording BP every 20 minutes
from 6 AM to 10 PM and every 30 minutes
from 10 PM to 6 AM66 As in the case of
home BP, interdialytic SBP increases, albeit at a slower rate of 2.5 mmHg every
10 hours.67,68 Because a much greater
number of measurements during the interdialytic interval are typically available
compared with home BP, patterns of BP
can be evaluated. Figure 1 illustrates the
pattern of BP and heart rate over an interdialytic interval. Among HD patients,
ambulatory BP monitoring remains a research technique.
In approximately 10%15% of patients, instead of decreasing, BP paradoxically increases during dialysis.69 These
patients have intradialytic hypertension.
Intradialytic hypertension is dened in
different ways. These denitions include
the following: (1) a discrete change in BP
from predialysis to postdialysis in a certain
number of dialysis treatments; (2) regression of all intradialytic BP with a slope .0;
and (3) a change of .0 mmHg from predialysis to postdialysis. Intradialytic hypertension is associated with greater
short-term (6-month) mortality in HD
patients.70 In another cohort, an increase
in SBP by .10 mmHg during HD occurred in approximately 10% of incident
patients. Although this increase in SBP
during HD was associated with decreased
2-year survival, these ndings were limited to patients with predialysis SBP of
,120 mmHg. 71 Although the exact
mechanism of this relationship is unclear,72,73 a study shows that intradialytic
hypertension in HD patients using denition 2 noted above is associated with both
volume excess and interdialytic hypertension.74 Another study, using denition
1, conrmed the association between intradialytic hypertension and interdialytic
hypertension.75
At least two studies suggest that lowering dry weight may improve interdialytic hypertension. Cirit et al. treated
Journal of the American Society of Nephrology
seven hypertensive patients on HD with

marked cardiac dilation that experienced
paradoxical hypertension during dialysis.76 After probing dry weight, both BP
and postdialysis weight was reduced; the
BP reduction was 46/22 mmHg and postdialysis weight was reduced by 6.7 kg. The
authors concluded that BP may paradoxically rise with ultraltration when patients
are volume overloaded. Dry weight was reduced progressively in the randomized
Dry-Weight Reduction in Hypertensive
Hemodialysis Patients (DRIP) trial, as discussed below.77 Those patients with intradialytic hypertension who had additional
ultraltration and therefore a reduction in
dry weight had improvement in both intradialytic and interdialytic hypertension.74
This suggests that an appropriate therapy
for this condition would be to further lower
dry weight. However, the phenomenon of
intradialytic hypertension is complex and
incompletely understood; pilot studies suggest that endothelial dysfunction may be
operative in its pathogenesis.78
Home BP measurement is a practical
way to measure and manage hypertension
among HD patients. The targets of therapy
using home BP monitoring will need to be
dened in future trials. Guidelines of the
American Heart Association dene hypertension as home BP of at least 135/85
mmHg45; lowering BP in the interdialytic
period to at least 140/90 mmHg appears
to be a reasonable goal (Table 1).
NONPHARMACOLOGIC
TREATMENT
Once an accurate diagnosis is made, the

therapy of hypertension among HD
patients rests on nonpharmacologic
management. Although scarcely studied,
one small study lasting 6 months
showed a benecial effect of exercise on
BP and medication requirements.79 Exercise consisted of using a stationary bicycle during dialysis. 79 Besides this
promising strategy, the nonpharmacologic management of hypertension is
based on four principles: dietary sodium
restriction, individualizing dialysate sodium, the management of dry weight,
and providing an adequate duration of
J Am Soc Nephrol 25: 16301646, 2014
www.jasn.org
BRIEF REVIEW
dialysis. These principles are further discussed.

Dietary Sodium Restriction
Dietary sodium restriction limits interdialytic weight gain and improves the
feasibility of achieving dry weight.80,81
Instead of restricting dietary sodium, patients on HD are sometimes prescribed
uid-restricted diets. With the exception
of treating hyponatremia, there is no scientic basis for prescribing a uid-restricted
diet in these patients.82
Recent guidelines suggest that elderly
persons and individuals with CKD are
most likely to derive the greatest benets
from dietary sodium restriction.83 These
guidelines are even stricter on sodium intake than those advocated earlier (2 g/d).
Dietary sodium restriction to no more
than 1.5 g sodium (or approximately
65 mmol) per day is now recommended.
Although no randomized trials have
been performed among patients with
ESRD, observational studies among
long-term HD patients suggest that restricting dietary sodium and achieving dry
weight can improve LVH.84
Individualizing Dialysate Sodium
Figure 1. Modeled trended cosinor BP and pulse rate in HD patients. Notice the linear
trend in SBP, DBP, and pulse pressure but the lack thereof in heart rate. Reprinted from
reference 67, with permission.
J Am Soc Nephrol 25: 16301646, 2014
High sodium dialysis was initially prescribed to provide hemodynamic stability,

fewer disequilibrium symptoms, and fewer
muscle cramps.85 Early studies found that
high sodium dialysate among normotensive patients reduced dialysis-induced hypotension and was not associated with
long-term hypertension.86 However, its effect among those with hypertension was
less clear.86 A double-blind crossover trial
in seven dialysis patients found that compared with dialysate sodium of 135 mEq/L,
both dialysate sodium of 143 mEq/L or
sodium gradient dialysate of 160133
mEq/L were associated with greater interdialytic weight gain (2.2, 2.6, and 2.8 kg
respectively).87 Another study showed
that interdialytic weight gain and thirst
can be provoked with the prescription of
hypertonic dialysate.88 These ndings are
now being recognized as important treatment targets.89 The prescription of high
sodium dialysate allows increased uid
volume removal and better hemodynamic
stability. However, it provokes increased
1633
BRIEF REVIEW
www.jasn.org
Table 1. Diagnosis and epidemiology

of hypertension
Summary Statements
1. Diagnosing hypertension in dialysis patients
is challenging.
2. Compared with predialysis and postdialysis
BP measurements, diagnosis of
hypertension is better made by using home
BP recordings or interdialytic ambulatory BP
recordings.
3. Hypertension is frequently treated with
antihypertensive drugs, but remains
adequately controlled in only a minority of
the patients.
4. Hypertension in children on dialysis is as
prevalent as in adults and given the life-time
risk needs to be controlled.
thirst, increased interdialytic weight gain,

and more uid removal with next dialysis.
It may therefore provoke hemodynamic
instability and prescription of even a
higher dialysate sodium, perpetuating a vicious cycle.90 In some patients, worsening
of BP control may ensue.86 The vicious
cycle can be interrupted by individualizing
dialysate sodium concentration,91 which
may improve BP control.92 In a pilot study
of 16 patients, dialysate sodium was progressively decreased in four phases from
137.8 to 135.6 mmol.93 As a result of this
maneuver, the net sodium loss increased
nearly 100 mmol from 383 to 480 mmol
per treatment; this was associated with reduced interdialytic weight gain and BP.93
Thus, facilitating diffusive sodium losses in
addition to convective loss can increase net
sodium removal and therefore lower BP.
Sodium ramping that is prescribed to offset intradialytic hemodynamic instability
is associated with fewer hypotensive episodes on dialysis but greater interdialytic
fatigue and thirst, greater interdialytic
weight gain, and hypertension.94 Interdialytic 24-hour ambulatory BP increased
when the time-averaged concentration of
sodium was extremely elevated at 147
mEq/dl.95 Therefore, one sodium prescription may not t all patients.
In a nonrandomized trial, improvement in nocturnal mean arterial pressure
was found among PD patients who were
prescribed a low dialysate sodium. 96
However, if the low dialysate sodium
was not accompanied by a reduction in
1634
dry weight, BP did not change. Prescribing both low dialysate sodium and challenging dry weight may improve BP
control over and above one strategy
alone. In addition, BP increments provoked by higher sodium dialysate can be
adequately controlled by the adjustment
of dry weight.97
Management of Dry Weight
The management of dry weight poses

several challenges. First and foremost,
there is no universally agreed-upon denition of dry weight. Sinha and Agarwal
dene dry weight as the lowest tolerated
post dialysis weight achieved via gradual
change in postdialysis weight at which
there are minimal signs or symptoms of
either hypovolemia or hypervolemia.98
Assessment of Dry Weight
The physical examination is notoriously
unreliable in excluding volume overload.
For example, pedal edema does not correlate with dry weight very well. In a casecontrol study, Agarwal et al. found that
inferior vena cava diameter, blood volume
monitoring, plasma volume markers, and
inammation markers were not determinants of edema.99 For the most part, the
assessment and achievement of dry weight
is an iterative process that often provokes
uncomfortable intradialytic symptoms
such as hypotension, dizziness, cramps,
nausea, and vomiting. These symptoms
often lead to interventions such as cessation of ultraltration, administration of
saline, premature cessation of dialysis, or
placing the patient in the head-down
(Trendelenburg) position. Interestingly,
placing the patient in the head-down position does little to protect the BP and this
practice is questionable100; raising the leg
passively without lowering the head can,
however, be effective to raise ventricular
lling pressure.101 Often physicians will
respond to these distressing symptoms
by raising dry weight, and then adding
more antihypertensive medication. Paradoxically, this may make subsequent
achievement of dry weight even more difcult. However, if dry weight is reduced
gently either by setting the ultraltration goal to just a little above the previous
achieved postdialysis weight (e.g., by
0.20.3 kg in an adult) either without

changing the dialysis time or better still
by prolonging the dialysis time to allow
for slower ultraltration with dialysis, dry
weight can then be successfully achieved.
Benets of Probing Dry Weight
Dry weight was probed without changing
the dialysis time in a randomized controlled trial of hypertensive HD patients.77
Notably, in this study, patients with obvious volume overload were excluded. Thus,
the study tested the hypothesis that hypertension among HD patients who do not
manifest overt signs of volume overload is
mediated by excess volume. Interdialytic
ambulatory BP monitoring was performed three times (at baseline, 4 weeks,
and 8 weeks) in 50 patients randomized
to a control group and 100 patients randomized to ultraltration group. Ambulatory BP was reduced within 4 weeks by
11/6 mmHg77 (Figure 2). This level of
BP reduction was achieved despite stable
concurrent use of 2.7 antihypertensive
drugs. The magnitude of reduction in BP
is therefore much larger than what would
be expected by adding an additional antihypertensive agent. Because the control
group had a placebo effect, subtracting
this effect from the intervention group resulted in still a signicant ambulatory BP
reduction of 7/3 mmHg. This antihypertensive effect was sustained for 8 weeks of
observation. Despite provoking occasional uncomfortable intradialytic symptoms, the quality of life was not impaired.
Even in this randomized trial, the presence
or absence of edema, which is often taken
as a reliable sign of volume overload, had
no predictive value in separating the responders from nonresponders. Furthermore, 10% of the patients in the control
group developed accelerated hypertension, dened as BP $175/105 mmHg by
interdialytic ambulatory monitoring. This
study provides strong support for the hypothesis that among HD patients, dry
weight reduction is an effective strategy
for reducing BP.
Observational studies also support the
practice of probing dry weight. In 1969,
Vertes et al. reported that 35 of 40 patients
became normotensive by achieving dry
weight.102 In a more recent report from
J Am Soc Nephrol 25: 16301646, 2014
www.jasn.org
BRIEF REVIEW
primary strategy had the following benets: lower antihypertensive drug use (7%
versus 42%), lower interdialytic weight
gain, lower left ventricular mass, better diastolic and systolic left ventricular function, and fewer episodes of intradialytic
hypotension. These observations are important and of clinical relevance; they
suggest that probing for dry weight as opposed to adding more antihypertensive
drugs perhaps diminishes the risk for cardiac remodeling and mitigates LVH, and
preserves systolic and diastolic left ventricular function. Although a case-control
study cannot assert causation, the results
of this study support the use of nonpharmacologic therapies in the management
of patients with ESRD.
Figure 2. The effect of dry weight reduction on interdialytic ambulatory SBP and DBP in
hypertensive HD patients. The mean SBPs (A) and DBPs (B) are shown for the baseline
control and ultraltration groups. The mean changes in BP are shown for weeks 4 and 8 after
randomization (solid arrows), and the mean differences in BPs (dotted arrows) between the
two groups at each 4-week interval. The numbers next to the dotted lines connecting the
data points are the mean changes in BP between groups at 4 and 8 weeks after randomization. The 95% condence intervals (95% CIs) are given in parentheses. Signicant differences between groups or within groups are as indicated as follows: *P,0.05; P,0.01;
P,0.001. The ultraltration-attributable change in SBP was 26.9 mmHg (95% CI, 212.4
to 21.3 mmHg; P=0.02) at 4 weeks and 26.6 mmHg (95% CI, 212.2 to 21.0 mmHg;
P=0.02) at 8 weeks. The ultraltration-attributable change in DBP was 23.1 mmHg (95% CI,
26.2 to 20.02 mmHg; P=0.05) at 4 weeks and 23.3 mmHg (95% CI, 26.4 to 20.2 mmHg;
P=0.04) at 8 weeks. Reprinted from reference 77, with permission.
Turkey, Kayikcioglu et al. compared the

benet of nonpharmacologic therapy versus pharmacologic therapy for control of
left ventricular mass among HD patients.103 In a case-control study, patients
who had been treated at one center with
J Am Soc Nephrol 25: 16301646, 2014
salt restriction and dry weight reduction

were compared with patients at another
center where antihypertensive-based therapy was the primary method for management of hypertension. The center using
dry weight and salt restriction as a
Dry Weight and Outcomes

Studies among HD patients in both
adults and children suggest that managing intradialytic relative plasma volume
(RPV) may reduce the number of hospital admissions caused by uid overload,104,105 may improve BP control, and
may decrease hypotension-associated
dialysis symptoms.106 It is possible that
the latter benet is, in part, related to
diminished use of antihypertensive
medication. Accordingly, monthly monitoring of RPV and home BP may offer
an attractive way to assess the adequacy
of volume control among HD patients.
To note, the multicenter randomized
Crit-Line Intradialytic Monitoring Benet (CLIMB) trial107 demonstrated that
RPV-guided therapy was associated with
worse outcomes, contrary to the original
hypothesis. The CLIMB trial randomized 227 HD patients to RPV monitoring
and 216 to conventional monitoring for
6 months to test the hypothesis that
RPV-guided monitoring would result
in reduced hospitalization rates. Compared with the conventional group, the
adjusted risk ratios (RR) were 1.61 (95%
condence interval [95% CI], 1.15 to
2.25; P=0.01) for nonaccess hospitalization and 1.52 for access-related hospitalization (P=0.04) in the RPV-guided
monitoring group. Mortality was 8.7%
and 3.3% (95% CI, 1.02 to 2.28;
P=0.021) in the RPV-guided monitoring
and conventional monitoring groups,
1635
BRIEF REVIEW
www.jasn.org
respectively. An elaborate protocol was

available to guide uid management
based on RPV-guided monitoring; algorithm use was encouraged but not
mandated. Furthermore, highly variable
implementation of the monitoring and
interventional algorithm occurred
within and across dialysis units. At baseline, as determined by RPV slope patterns, patients in the conventional group
appeared to be more volume overloaded
compared with the RPV-guided group.
At 6 months, both groups had similar
RPV slopes. Thus, the conventional
group appeared to have had greater volume challenge than the intervention
group. Although this was a randomized
trial, the ndings should be interpreted
with caution for the above reasons.
To study the effect of volume status on
mortality, Wizemann et al. followed 269
prevalent HD patients for several
years.108 They measured hydration state
using a body composition analyzer. If
there was .15% excess of extracellular
water (2.5 L volume excess), they classied such patients as volume overloaded;
25% of the patients had excess extracellular uid (ECF) volume. In a multivariate adjusted analysis, they found that
excess volume was associated with high
mortality. Compared with those without
excess ECF volume, the hazard ratio of
mortality with excess uid volume was
2.1 (95% CI, 1.39 to 3.18; P=0.003). Although the study did not examine the
effect of reduction in ECF volume on
subsequent outcomes, such studies
need to be performed in the future.
Inrig et al. compared the change in
pulse pressure during dialysis as a risk
factor for hospitalization and mortality
among prevalent HD patients participating in a randomized controlled trial.109
They found that patients who had the
least change in pulse pressure from before to after dialysis had clinical characteristics indicating volume overload.
Among these patients, lowering of the
pulse pressure from before to after dialysis was associated with lower hospitalization and mortality outcomes. Because
pulse pressure is largely driven by SBP, it
is likely that lowering of pulse pressure
with dialysis reects more volume loss
1636
and a lower ECF volume state, and may

provide better cardiovascular outcomes,
perhaps through less pressure/volume
stress on the heart.
Potential Hazards of Probing Dry Weight
There are potential hazards related to
probing dry weight, none of which have
been adequately examined.77 These include the following: (1) increased risk
of clotted angioaccess, (2) increased
rate of attrition in residual renal function, and (3) complications related to
intradialytic hypotension. Intradialytic
hypotension, besides requiring more
nursing interventions, can be complicated
by cerebral hypoperfusion, seizures, myocardial dysfunction, and mesenteric ischemia. Furthermore, it has been associated
with mortality.110 The relative risks and
benets of probing dry weight need to
be examined in long-term randomized
trials.
Providing Adequate Duration of
Dialysis
The European Best Practice Guidelines

recommend that dialysis should be delivered at least three times a week and the
total duration should be at least 12 hours
per week, unless substantial residual renal function is present.111 An increase in
treatment time and or frequency should
be considered in patients who experience hemodynamic instability or remain
hypertensive despite maximal possible
uid removal.
In the United States, a recent study
reported that the average duration of
dialysis among 32,065 participants in the
ESRD Clinical Performance Measures
Project was 217 minutes.112 The interquartile range was 195240 minutes.
This means that one-quarter of the patients were receiving ,3 hours and 15
minutes of dialysis and only one-quarter
of the patients were receiving .4 hours
of dialysis.
Although what constitutes an adequate dialysis is still debated, it is clear
that patients who shorten treatment have
hypertension that is more difcult to
control.5 Patients who dialyze 8 hours
three times a week have excellent BP
control, minimal requirement for
antihypertensive drugs, and excellent

long-term survival.41,113 In a randomized crossover trial of 38 patients, the
effects of 4-hour dialysis to 5-hour dialysis were evaluated.114 Hemodynamic
stability and hypotensive episodes were
fewer with longer dialysis, especially
among older patients (aged .65 years).
However, these data are difcult to generalize because treatment was evaluated
only over 2 weeks and those requiring
.4 L ultraltration were excluded. Longer or more frequent dialysis sessions, in
general, are associated with less hemodynamic instability, better achievement
of postdialysis dry weight, better control
of BP, and the reduced need for antihypertensive drugs.
FREQUENT DIALYSIS AND ITS

EFFECT ON BP
Observational studies suggest that conversion of patients from three times a

week conventional dialysis to nocturnal
dialysis may improve BP and left ventricular mass.115 In a cumulative analysis
of 72 patients from nine centers it was
noted that predialysis SBP and DBP fell
within 1 month of dialysis by 13/7
mmHg from 163/94 mmHg.116 This reduction was accompanied by a 1% decline in postdialysis weight. Although BP
did not change after 1 month, the number of antihypertensive agents declined
signicantly. At baseline, 54% of patients
were not taking antihypertensive drugs,
whereas at 12 months after switching to
daily dialysis, 75% were not taking antihypertensive agents.
Several observations have suggested
improvements in BP and left ventricular
mass among patients undergoing more
frequent dialysis. For example, Chan
et al. reported an improvement in both
SBP and DBP, a reduction in antihypertensive drugs and doses, and a reduction
in left ventricular mass in patients undergoing nocturnal dialysis. 115 This
group also reported an improvement in
pharyngeal size among nocturnally dialyzed patients. 117 This may improve
sleep apnea and consequently ambulatory BP. Another mechanism of BP
J Am Soc Nephrol 25: 16301646, 2014
www.jasn.org
reduction with frequent dialysis is suggested to be an increase in arterial compliance and consequently improvement
in baroreex sensitivity.118 Other mechanisms may be better volume and toxin
removal.119
A randomized controlled trial assigned 52 HD patients to either frequent
dialysis, six nights per week, or conventional three times a week treatment. In
the frequent dialysis group, the results
showed an improvement in cardiac magnetic resonanceimaged left ventricular
mass and a reduction in the need for antihypertensive medications.120 The Frequent Hemodialysis Network (FHN)
study randomized HD patients to either
conventional dialysis three times weekly
or more frequent in-center dialysis; the
primary endpoint was an improvement
in joint composite end points of either
(1) death or LVH or (2) death or physical
health composite. The primary end
point was met, but perhaps the most notable ndings were an improvement in
SBP, a reduction in antihypertensive
drug use, and an improvement in left
ventricular mass.121 These ndings suggest better achievement of dry weight in
these patients.122 Improvement in SBP
was also noted in the companion FHN
Nocturnal trial.123 Increasing the treatment duration may improve hemodynamic stability of dialysis and make the
procedure more tolerable, but it is not a
requirement for improvement in left
ventricular mass. Shortening the procedure to tailor dialysis to a minimum
Kt/V may provoke intradialytic symptoms,
postdialysis fatigue, and nonadherence
to therapy; thus, this is not recommended.124 Normotension can be achieved
independently of the duration of dialysis
if the control of volume is adequate.125 In
fact, left ventricular mass index was also
improved to a comparable degree in
DRIP trial participants, in which the duration of dialysis was not altered but the
dry weight was challenged.126
PHARMACOLOGIC TREATMENT
All classes of antihypertensive drugs,

except diuretics, are useful for managing
J Am Soc Nephrol 25: 16301646, 2014
hypertension in HD patients.127 Diuretics are generally ineffective at very low

GFR. There is no role of loop diuretics
even when given in a high dose (e.g., as
high as 250 mg intravenously of furosemide) among anuric HD patients. 128
Tissue Doppler imaging revealed that
central cardiac hemodynamics were unaltered when anuric HD patients were
given even such high doses of loop diuretics. Given the ototoxicity associated
with high doses of loop diuretics, their
use, especially in high doses, is not recommended. Further research is needed
to clarify the role of loop diuretics
among patients with substantial residual
renal function (e.g., patients new to
long-term dialysis). Consideration of
pharmacokinetics is important when
prescribing these drugs.129 In general, if
patients are volume overloaded, antihypertensive medications are less effective.
Paradoxically, among HD patients, a
greater use of antihypertensive medications is associated with a higher BP.130
However, causality must not be assumed. It is more likely that excessive
antihypertensive medication may interfere with achievement of dry weight.
Drugs that block the renin-angiotensin
system are often recommended as rstline therapy for HD patients because of
their tolerability and extrapolated cardiovascular benets in the general population
with heart and kidney disease. Only one
prospective trial compared an angiotensinconverting enzyme inhibitor (fosinopril)
versus placebo in HD patients, all of which
had LVH. Although hypertension was
not an inclusion criterion, all patients
underwent a single-blind run-in period
with 5 mg of fosinopril, and those who
experienced symptomatic hypotension
or had a SBP ,95 mmHg 46 hours after
test dose were excluded. Subsequently, in
the Fosinopril and Dialysis Trial, 400 HD
patients received 20 mg of fosinopril versus placebo in an equal ratio. After 4 years
of follow-up, there were no differences
between the two treatment groups in
the primary end point of cardiovascular
events that included cardiovascular
death.131 Another smaller trial compared
candesartan versus placebo in HD patients, but noted a nearly 3-fold reduction
BRIEF REVIEW
in cardiovascular events with active treatment versus placebo.132 These conicting

results indicate the need for larger studies.
There are no studies in PD patients, nor
are there any studies in HD patients with
diabetes.
b-Blockers may be an effective therapeutic strategy in HD patients with reduced ejection fraction (,35%). One
study randomized 114 (not necessarily
hypertensive) patients with dilated cardiomyopathy to 25 mg of carvedilol twice
daily or placebo for 2 years. b-Blocker
treatment reduced hospitalizations (RR,
0.44) and all-cause death (RR, 0.51).133
Regrettably, the reduction in all-cause
mortality with antihypertensive drug therapy in HD patients has not been realized
with adequately powered randomized
controlled trials. This may be due to multiple reasons, including the low numbers
of patients. Nonetheless, meta-analyses
of these trials show improvement in the
cardiovascular event rate.134,135 These
benets are especially seen among individuals who have hypertension.135
The recently reported Hypertension in
HemoDialysis Patients Treated with Atenolol or Lisinopril (HDPAL) trial randomly assigned 200 patients to either
open-label lisinopril (n=100) or atenolol
(n=100) each administered three times
per week after dialysis. The HDPAL trial
aimed to determine whether angiotensinconverting enzyme inhibitorbased antihypertensive therapy causes a greater
regression of LVH compared with
b-blockerbased antihypertensive therapy among maintenance HD patients
with echocardiographic LVH and hypertension.136 Monthly monitored home BP
was controlled to ,140/90 mmHg with
medications, dry weight adjustment, and
sodium restriction. The primary outcome
was the change in the left ventricular mass
index from baseline to 12 months. At
baseline, 44-hour ambulatory BP was
similar in the atenolol (151.5/87.1
mmHg) and lisinopril groups, and improved similarly over time in both groups.
However, monthly measured home BP
was consistently higher in the lisinopril
group despite needing a greater number
of antihypertensive agents and a greater
reduction in dry weight. An independent
1637
BRIEF REVIEW
www.jasn.org
data safety monitoring board recommended early termination of the trial because of
cardiovascular safety. Serious cardiovascular events occurred in 16 participants in the
atenolol group who had 20 events and in 28
participants in the lisinopril group who
had 43 events (incidence rate ratio [IRR],
2.36; 95% condence interval, 1.36 to 4.23;
P=0.001). Combined serious adverse
events of myocardial infarction, stroke,
hospitalization for heart failure, or cardiovascular death occurred in 10 participants
in the atenolol group who had 11 events
and in 17 participants in the lisinopril
group who had 23 events (IRR, 2.29;
95% CI, 1.07 to 5.21; P=0.02). Hospitalizations for heart failure were worse in the
lisinopril group (IRR 3.13; 95% CI, 1.08 to
10.99; P=0.02). All-cause hospitalizations
were higher in the lisinopril group (IRR,
1.61; 95% condence interval, 1.18 to 2.19;
P=0.002). The left ventricular mass index
improved with time; no difference between drugs was noted. These data appear
to suggest that among maintenance dialysis patients with hypertension and LVH,
atenolol-based antihypertensive therapy
may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations. Larger
multicenter trials should be performed
to conrm these provocative data from a
single center.
NONVOLUME-DEPENDENT
CAUSES OF HYPERTENSION IN
DIALYSIS PATIENTS
An increase in BP is a well recognized

complication of erythropoietin therapy in
HD patients.137 Hypertension is common
with erythropoietin therapy, with approximately 30% of patients either developing
hypertension or requiring an adjustment
in antihypertensive medications.138,139
The etiology of hypertension with erythropoietin therapy is not clear. The incidence
of erythropoietin-induced hypertension
correlates with the erythropoietin dose
but appears to be independent of its effect on red blood cell mass and viscosity.140,141 Available data suggest that the
most likely mechanisms involve either an
increase in production or an enhanced
1638
response to the effect of various vasoactive substances. 142,143 Several studies

have found that erythropoietin-induced
hypertension in hemodialyzed patients is
associated with either a signicantly increased circulating endothelin-1 concentration or enhanced vasoconstrictive response
to endothelin-1.144146 Erythropoietin
treatment has also been shown to be associated with an accentuated increase in
the BP response to angiotensin II infusion
compared with the BP response before
erythropoietin therapy.147 This apparent
increased sensitivity to angiotensin II correlated with the erythropoietin-induced
increase in BP. Studies have also shown
noradrenergic hypersensitivity in hemodialyzed patients with erythropoietininduced hypertension.148
The effect of erythropoietin on BP can
be missed because of variability in BP from
predialysis to postdialysis and the lack of
home or ambulatory BP measurements.
Studies that failed to detect increases in BP
with erythropoietin therapy may have
managed hypertension more aggressively
through the prescription of antihypertensive drugs or closer attention to dry weight.
Erythropoietin therapy was an independent predictor of hypertension diagnosed
by ambulatory BP monitoring.8 Some
studies show an association of erythropoietin use with nondipping.149 Increase in
BP with erythropoietin occurs more commonly in individuals with preexisting hypertension150,151 or a family history of
hypertension.152
Prevention of erythropoietin-induced
hypertension, and other complications,
is a clinical challenge with several possible
management strategies. Recommended
strategies, with little good evidence to
support these practices, have included the
following: changing the route of administration (subcutaneous versus intravenous), reducing the goal hemoglobin level
(especially in patients who are unresponsive to erythropoietin therapy), starting
with a low erythropoietin dose and increasing the dose slowly, and avoiding the
use of erythropoietin altogether.
Sleep apnea is very common in dialysis
patients and is often associated with volume overload. Hypopneic spells during
the night lead to nocturnal hypoxemia and
provoke intense sympathetic arousal and

an increase in nocturnal BP.153 Table 2
summarizes the key points in the management of hypertension.
Hypoxemia that characterizes sleep
apnea in patients with ESRD may cause
hypertension. 154 Patients with ESRD
with sleep apnea have shown a 7-fold
higher prevalence of resistant hypertension than individuals in the general hypertension population.155 In the recumbent
position, the volume overload is redistributed from the legs to the chest and
neck areas and may induce a peripharyngeal and upper airway resistance.156
Volume overload and the specic redistribution described in patients with
ESRD may be not only a consequence
but also an important cause of obstructive sleep apnea.157
RELATIONSHIP OF BP AND
MORTALITY
Among HD patients, the relationship of BP

with cardiovascular outcomes is a subject of
much controversy.158164 As previously
discussed, controversy relates to the specic relationship between the BP measurement times and technique (predialytic,
postdialytic, or intradialytic BP measurements or interdialytic ambulatory BP) and
morbidity and mortality. Some studies
suggest an association of high BP with
strokes,165,166 cerebral atrophy,167 cardiovascular events,168 complex cardiac arrhythmias,169 the development of congestive
heart failure,161 and all-cause mortality.170 Other studies suggest that low BP
measured either predialysis or postdialysis is associated with increased mortality.164,171173 This association of low BP
and mortality is further magnied when
BP is considered as a time-dependent covariate.173 High BP measured either before dialysis or after dialysis are either not
associated or minimally associated with
increased mortality. The phenomenon of
lower BP being associated with increased
mortality has been labeled as reverse epidemiology of hypertension. This has
raised concerns regarding lowering of
BP among hypertensive HD patients.174,175
Other studies have demonstrated a direct
J Am Soc Nephrol 25: 16301646, 2014
www.jasn.org
Table 2. Management of hypertension

Summary Statements
1. Volume overload is often an overlooked
factor in managing hypertension.
Erythropoietin-induced hypertension and
untreated sleep apnea are other important
causes.
2. Volume overload is associated with
increased mortality in HD patients.
3. The iterative trial-and-error method of dry
weight assessment remains the current
clinical standard in assessing volume status.
4. Dietary salt restriction and individualizing
dialysate sodium prescription may improve
the feasibility of achieving dry weight.
5. Probing dry weight can improve BP among
hypertensive HD patients. The long-term
risks and benets of probing dry weight
need to be examined in future trials.
6. Delivery of dialysis of at least 4 hours
duration three times a week may facilitate
volume and hypertension control.
7. Antihypertensive drugs are frequently
needed to control hypertension but are an
adjunct to facilitate volume control.
Diuretics have little to no role in patients
with ESRD. b-blockers may be preferred to
other agents.
relationship between BP and mortality.170,176 Consideration of the patient

characteristics, dialysis practices, and
BP measurement techniques is useful
when evaluating these outcomes.
Consideration of the level of illness and
the vintage of the patient are also instructive
to ascertain the value of hypertension as a
risk factor among HD patients. Examining
the outcomes of 2770 patients on PD
provides such insights.15 These patients
were studied between 1997 and 2004 and
had been on PD for at least 180 days in
England and Wales. In a fully adjusted
analysis, greater SBP, DBP, mean arterial,
and pulse pressure were associated with decreased mortality among patients who had
been on dialysis for ,1 year. However,
greater SBP and pulse pressure (but not
mean arterial pressure and DBP) were associated with increased mortality among
patients who had been on PD for $6 years.
In a subgroup of patients who were placed
on the transplant waitlist within 6 months
of starting RRT and were presumably
healthier, greater SBP, DBP, mean arterial
or pulse pressure were not associated with
J Am Soc Nephrol 25: 16301646, 2014
decreased mortality in the rst year. Similarly, among 16,959 dialysis patients in the
United States, low SBP (,120 mmHg) was
associated with increased mortality in years
1 and 2.177 However, high SBP ($150
mmHg) was associated with increased
mortality among patients who survived at
least 3 years.177
Regional differences in mortality are
unlikely to be caused by patient-specic
characteristics alone. Forexample, a center
in Tassin, France, reported a mortality rate
of 45 per 1000 patient-years.176 By contrast, Degoulet et al., also from France,
reported a mortality rate of 96 per 1000
patient-years.178 Differences in outcomes
may be the result of center-specic practices. Patients reported by Charra et al. in
Tassin, France, are dialyzed long hours
with low sodium dialysate and are given
low-sodium bread from the dialysis
unit.176 The vast majority of these patients
become normotensive without needing
antihypertensive drugs.
BP measurement technique is also
quite likely to contribute to variation in
the relationship between BP and outcomes. For example, Amar et al. were
the rst to discover the strong relationship
between ambulatory BP and mortality.53
These authors reported that nocturnal
SBP was directly related to mortality.
Agarwal et al. have used ambulatory BP
to detect its relationship with mortality.
In a cohort of approximately 150 patients,
the authors found a direct and statistically
signicant relationship of both home and
ambulatory BP with mortality.54 No such
relationship was detectable using predialysis and postdialysis BP recordings. In a
larger cohort followed for a longer time,
the authors found a W-shaped relationship between both ambulatory BP and
home BP and all-cause mortality64 At extremes of BP, mortality was noted to be
high. Compared with ambulatory BP, the
optimal BP ranges for home BP were approximately 10 mmHg higher.
HYPERTENSION IN PEDIATRIC
DIALYSIS PATIENTS
Young adults with childhood-onset ESRD

have signicantly elevated cardiovascular
BRIEF REVIEW
risk compared with the general population. Data from the Late Effects of Renal
Insufciency in Children cohort study of
249 Dutch adult patients with onset of
ESRD between 0 and 14 years of age
demonstrated that the overall mortality
risk of the patients with ESRD was 31 times
that of age-matched Dutch citizens.179
Cardiovascular disease accounted for
41% of all mortalities, with cardiac death
becoming the most common cause of
mortality after 10 years of receiving
RRT.179 Similarly, among 1380 patients
with childhood-onset ESRD who died before aged 30 years, 23% of deaths were
cardiovascular in origin; the cardiovascular death rate was 1000 times higher
among children with ESRD than in the
general population, and was 100 times
higher among young adults with ESRD
than in the general population.180 Although the number of patients with
childhood-onset ESRD is small compared
with the overall adult ESRD population,
they constitute a unique group in whom
control of cardiovascular risk factors is key
to ensuring long-term survival.
As in adult ESRD patients, hypertension is the most common modiable
cardiovascular risk factor in children on
dialysis. Mitsnefes et al.181 reported that
approximately 60% of pediatric dialysis
patients had uncontrolled hypertension,
dened as measured BP$95th percentile. Young age, recent dialysis initiation,
and HD modality were identied as risk
factors for having uncontrolled BP. Similar poor control of hypertension using
predialysis and postdialysis BP measurements in American dialysis patients has
been reported by Chavers et al.6 for HD
patients and Halbach et al.182 for both
HD and PD patients. In the latter study,
demographic factors such as young age
and black race and treatment factors
such as prescription of antihypertensive
medications were also identied as risk
factors for poorly controlled hypertension. More recent data from the European Registry for Children on Renal
Replacement Therapy on BP control
among pediatric ESRD patients in
Europe, including patients receiving
HD, PD, and postrenal transplant, conrmed the high rate of hypertension in
1639
BRIEF REVIEW
www.jasn.org
pediatric ESRD. Hypertension was present in 69.4% of HD patients (using BP

recordings in the peridialytic period),
68.6% of PD patients, and 66.9% of
transplant recipients.183 Among dialysis
patients, younger age, recent dialysis initiation, and HD modality were the most
important risk factors for hypertension.183 Of note, all of these studies are
notable for their reliance upon registry
data; thus, there is limited information
available on the technique and/or frequency of BP measurement, or the goals
of hypertension management.
LVH is the best-studied complication
of hypertension in pediatric dialysis patients. A study by Mitsnefes et al. demonstrated increased left ventricular mass
at the start of dialysis, and also showed
that this increase persisted over a mean
follow-up of 10 months.184 Risk factors
for LVH included anemia, longer duration of renal disease before start of
dialysis, and higher SBP. In a recent multicenter study from the International
Pediatric Peritoneal Dialysis Network,
LVH was present in 48% of hypertensive
PD patients, with uid overload, high
body mass index, and hyperparathyroidism being the primary determinants of
LVH. 185 Studies comparing the frequency of LVH in children on PD or
HD have had variable results. An American study showed that children on HD
had LVH more often (85%) than children on PD (68%).186 Similarly, a Finnish
study found that 45% of children on PD
had LVH; LVH in this study was highly
correlated with the severity of hypertension (pressure overload) and with hypervolemia as reected by the plasma atrial
natriuretic peptide level.187 On the contrary, the results from a German study
showed similar left ventricular mass index
with both modes of treatment.188 It is
therefore likely that the prevalence of left
ventricular in pediatric dialysis patients is
more dependent on the overall control of
BP and on volume status than on dialysis
modality.
Diagnosis of hypertension and achievement of BP control pose some unique
challenges in pediatric dialysis patients.
With respect to diagnosis, age-appropriate
normative values as published by the
1640
National High Blood Pressure Education

Program (NHBPEP) must be used, and BP
cuffs appropriate for the childs upper arm
must be selected.189 Normal BP in children is dened as a BP value below the
90th percentile for age, sex, and height,
and hypertension is dened as BP values
repeatedly at or above the 95th percentile.190 Thus, the clinician must consult
tables of normative BP values in order to
correctly categorize a childs BP as normal
or elevated. It should also be noted that
there are no existing consensus recommendations that specically address the
optimal BP treatment goal for children
on dialysis. Both the NHBPEP and the
Kidney Disease Outcomes Quality Initiative have recommended that hypertensive
children with CKD should be treated to a
BP below the 90th percentile,189,190 but
pediatric dialysis patients were not specifically mentioned in either of these reports.
Given that normalization of BP has been
shown to lead to regression of LVH in at
least one study of pediatric HD patients,191 recommendations to achieve a
BP value below the 90th percentile would
seem appropriate until further evidence
can be generated. Among pediatric patients on dialysis, further studies are
needed to dene the accuracy of peridialytic BP monitoring in determining interdialytic ambulatory BP.
Strategies to control hypertension in
pediatric dialysis patients are similar to
those used in adults, and include dietary
sodium restriction and control of volume
status. Vasodilating antihypertensive medications are generally avoided so as not to
compromise uid removal. A unique and
vexing issue in the treatment of hypertensive pediatric dialysis patients is how to
accurately assess and achieve dry weight.
Infants and young children in particular
are expected to demonstrate progressive
weight gain and linear growth, a process
that does not proceed in a predictable
linear manner.192 Thus, it is unreasonable
to expect that pediatric patients can
achieve and maintain a stable dry weight.
Two potential approaches to this problem
have been studied: bioimpedance analysis
and blood volume monitoring. In a recent
single-center study, use of bioimpedance
analysis to determine dry weight in a small
group of pediatric HD patients was associated with fewer episodes of pulmonary

edema and decreased prevalence of LVH
compared with a group of historical controls.193 A blood volume monitoring protocol in a multicenter study demonstrated
improved control of hypertension with
decreased need for antihypertensive medications, although no signicant change in
postdialysis weight was seen.106 In pediatric PD patients, a plasma atrial natriuretic
peptide level .3.0 nmol/L was felt to reect hypervolemia on one study,187 but
this nding has not yet been replicated.
Clearly, further renement of how to establish dry weight in pediatric dialysis patients is required.
Hypertension is an important clinical
problem in HD patients.Often medicationdirected approaches are utilized due to
its perceived simplicity, as in the general
population. However, nonpharmacologic
and dialytic approaches are more likely to
be successful and may target one of the
major factors that contribute to the development of congestive heart failure:
central pressure/volume overload. Use of
antihypertensive drugs may improve cardiovascular outcomes; b-blockers may
be a preferred drug class. More clinical
trials are needed to evaluate optimal individualized strategies for dening targets
for BP and controlling BP using pharmacologic and nonpharmacologic strategies
in HD patients.
ACKNOWLEDGMENTS
Review of an earlier version of this work by the
publication committee of the American Society of Hypertension and the Hypertension
Advisory Group of the American Society of
Nephrology is gratefully acknowledged. We
thank Tia A. Paul, University of Maryland
School of Medicine, Baltimore, for expert
secretarial support.
This work was supported, in part, by a
grant from the National Institutes of Health
(2R01-DK6203010) to R.A.
DISCLOSURES
None.
J Am Soc Nephrol 25: 16301646, 2014
www.jasn.org
REFERENCES
1. Agarwal R, Nissenson AR, Batlle D, Coyne
DW, Trout JR, Warnock DG: Prevalence,
treatment, and control of hypertension in
chronic hemodialysis patients in the United
States. Am J Med 115: 291297, 2003
2. Salem MM: Hypertension in the hemodialysis population: A survey of 649 patients.
Am J Kidney Dis 26: 461468, 1995
3. Rocco MV, Yan G, Heyka RJ, Benz R,
Cheung AK; HEMO Study Group: Risk factors for hypertension in chronic hemodialysis patients: Baseline data from the HEMO
study. Am J Nephrol 21: 280288, 2001
4. Raine AE, Margreiter R, Brunner FP, Ehrich
JH, Geerlings W, Landais P, Loirat C, Mallick
NP, Selwood NH, Tufveson G: Report on
management of renal failure in Europe, XXII,
1991. Nephrol Dial Transplant 7[Suppl 2]:
735, 1992
5. Rahman M, Fu P, Sehgal AR, Smith MC: Interdialytic weight gain, compliance with dialysis regimen, and age are independent
predictors of blood pressure in hemodialysis patients. Am J Kidney Dis 35: 257265,
2000
6. Chavers BM, Solid CA, Daniels FX, Chen SC,
Collins AJ, Frankeneld DL, Herzog CA:
Hypertension in pediatric long-term hemodialysis patients in the United States. Clin J
Am Soc Nephrol 4: 13631369, 2009
7. Grekas D, Bamichas G, Bacharaki D,
Goutzaridis N, Kasimatis E, Tourkantonis A:
Hypertension in chronic hemodialysis patients: Current view on pathophysiology
and treatment. Clin Nephrol 53: 164168,
2000
8. Agarwal R: Epidemiology of interdialytic
ambulatory hypertension and the role of
volume excess. Am J Nephrol 34: 381390,
2011
9. Boudville NC, Cordy P, Millman K, Fairbairn
L, Sharma A, Lindsay R, Blake PG: Blood
pressure, volume, and sodium control in an
automated peritoneal dialysis population.
Perit Dial Int 27: 537543, 2007
10. Velasquez MT, Lew SQ, von Albertini B,
Mishkin GJ, Bosch JP: Control of hypertension is better during hemodialysis than
during continuous ambulatory peritoneal
dialysis in ESRD patients. Clin Nephrol 48:
341345, 1997
11. Rocco MV, Flanigan MJ, Beaver S, Frederick
P, Gentile DE, McClellan WM, Polder J,
Prowant BF, Taylor L, Helgerson SD; Report
from the 1995 Core Indicators for Peritoneal
Dialysis Study Group: Report from the 1995
Core Indicators for Peritoneal Dialysis Study
Group. Am J Kidney Dis 30: 165173, 1997
12. Cocchi R, Degli Esposti E, Fabbri A,
Lucatello A, Sturani A, Quarello F, Boero R,
Bruno M, Dadone C, Favazza A, Scanziani R,
Tommasi A, Giangrande A: Prevalence of
hypertension in patients on peritoneal
J Am Soc Nephrol 25: 16301646, 2014
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
dialysis: Results of an Italian multicentre

study. Nephrol Dial Transplant 14: 1536
1540, 1999
Weiler EWJ, Saldanha LF, Khalil-Manesh F,
Prins BA, Purdy RE, Gonick HC: Relationship
of Na-K-ATPase inhibitors to blood-pressure
regulation in continuous ambulatory peritoneal dialysis and hemodialysis. J Am Soc
Nephrol 7: 454463, 1996
Tonbul Z, Altintepe L, Szl C, Yeksan M,
Yildiz A, Trk S: Ambulatory blood pressure
monitoring in haemodialysis and continuous ambulatory peritoneal dialysis (CAPD)
patients. J Hum Hypertens 16: 585589,
2002
Udayaraj UP, Steenkamp R, Caskey FJ,
Rogers C, Nitsch D, Ansell D, Tomson CR:
Blood pressure and mortality risk on peritoneal dialysis. Am J Kidney Dis 53: 7078,
2009
Konings CJ, Kooman JP, Schonck M,
Dammers R, Cheriex E, Palmans Meulemans
AP, Hoeks AP, van Kreel B, Gladziwa U,
van der Sande FM, Leunissen KM: Fluid
status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int 22: 477487,
2002
Tonbul Z, Altintepe L, Szl C, Yeksan M,
Yildiz A, Trk S: The association of peritoneal transport properties with 24-hour
blood pressure levels in CAPD patients.
Perit Dial Int 23: 4652, 2003
Wang MC, Tseng CC, Tsai WC, Huang JJ:
Blood pressure and left ventricular hypertrophy in patients on different peritoneal
dialysis regimens. Perit Dial Int 21: 3642,
2001
Cannella G, Paoletti E, Ravera G,
Cassottana P, Araghi P, Mulas D, Peloso G,
Delno R, Messa P: Inadequate diagnosis
and therapy of arterial hypertension as
causes of left ventricular hypertrophy in
uremic dialysis patients. Kidney Int 58: 260
268, 2000
Cheigh JS, Milite C, Sullivan JF, Rubin AL,
Stenzel KH: Hypertension is not adequately
controlled in hemodialysis patients. Am J
Kidney Dis 19: 453459, 1992
Bishu K, Gricz KM, Chewaka S, Agarwal R:
Appropriateness of antihypertensive drug
therapy in hemodialysis patients. Clin J Am
Soc Nephrol 1: 820824, 2006
Ertrk S, Ertu
g AE, Atesx K, Duman N, Aslan
SM, Nergiso
glu G, Diker E, Erol C, Karatan
O, Erbay B: Relationship of ambulatory
blood pressure monitoring data to echocardiographic ndings in haemodialysis
patients. Nephrol Dial Transplant 11: 2050
2054, 1996
Lazar AE, Smith MC, Rahman M: Blood
pressure measurement in hemodialysis patients. Semin Dial 17: 250254, 2004
Rahman M, Grifn V, Kumar A, Manzoor F,
Wright JT Jr, Smith MC: A comparison of
standardized versus usual blood pressure
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
BRIEF REVIEW
measurements in hemodialysis patients.

Am J Kidney Dis 39: 12261230, 2002
Inrig JK, Patel UD, Gillespie BS, Hasselblad
V, Himmelfarb J, Reddan D, Lindsay RM,
Winchester JF, Stivelman J, Toto R, Szczech
LA: Relationship between interdialytic
weight gain and blood pressure among
prevalent hemodialysis patients. Am J Kidney Dis 50: 108118, 2007
Agarwal R: Volume-associated ambulatory
blood pressure patterns in hemodialysis
patients. Hypertension 54: 241247, 2009
Thompson AM, Pickering TG: The role of
ambulatory blood pressure monitoring in
chronic and end-stage renal disease. Kidney Int 70: 10001007, 2006
Santos SF, Mendes RB, Santos CA, Dorigo
D, Peixoto AJ: Prole of interdialytic blood
pressure in hemodialysis patients. Am J
Nephrol 23: 96105, 2003
Mendes RB, Santos SF, Dorigo D, Mansoor
GA, Crowley ST, White WB, Peixoto AJ: The
use of peridialysis blood pressure and intradialytic blood pressure changes in the
prediction of interdialytic blood pressure in
haemodialysis patients. Blood Press Monit
8: 243248, 2003
Rohrscheib MR, Myers OB, Servilla KS,
Adams CD, Miskulin D, Bedrick EJ, Hunt
WC, Lindsey DE, Gabaldon D, Zager PG;
DCI Medical Directors: Age-related blood
pressure patterns and blood pressure variability among hemodialysis patients. Clin J
Am Soc Nephrol 3: 14071414, 2008
Argils A, Mourad G, Mion C: Seasonal
changes in blood pressure in patients with
end-stage renal disease treated with hemodialysis. N Engl J Med 339: 13641370,
1998
Conion PJ, Walshe JJ, Heinle SK, Minda S,
Krucoff M, Schwab SJ: Predialysis systolic
blood pressure correlates strongly with mean
24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J
Am Soc Nephrol 7: 26582663, 1996
Agarwal R, Peixoto AJ, Santos SF, Zoccali C:
Pre- and postdialysis blood pressures are
imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc
Nephrol 1: 389398, 2006
K/DOQI Workgroup: K/DOQI clinical practice guidelines for cardiovascular disease in
dialysis patients. Am J Kidney Dis 45[Suppl
3]: S1S153, 2005
Davenport A, Cox C, Thuraisingham R:
Achieving blood pressure targets during
dialysis improves control but increases intradialytic hypotension. Kidney Int 73: 759
764, 2008
Ifudu O, Dawood M, Homel P, Friedman
EA: Excess interdialytic weight gain provokes antihypertensive drug therapy in patients on maintenance hemodialysis. Dial
Transplant 26: 541, 1997
Iseki K, Nakai S, Shinzato T, Morita O,
Shinoda T, Kikuchi K, Wada A, Kimata N,
1641
BRIEF REVIEW
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
www.jasn.org
Akiba T: Prevalence and determinants of

hypertension in chronic hemodialysis patients in Japan. Ther Apher Dial 11: 183
188, 2007
Lpez-Gmez JM, Villaverde M, Jofre R,
Rodriguez-Bentez P, Prez-Garca R: Interdialytic weight gain as a marker of blood
pressure, nutrition, and survival in hemodialysis patients. Kidney Int Suppl 93: S63
S68, 2005
Rahman M, Dixit A, Donley V, Gupta S,
Hanslik T, Lacson E, Ogundipe A, Weigel K,
Smith MC: Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney
Dis 33: 498506, 1999
Luik AJ, Gladziwa U, Kooman JP, van Hooff
JP, de Leeuw PW, van Bortel LMAB,
Leunissen KML: Inuence of interdialytic
weight gain on blood pressure in hemodialysis patients. Blood Purif 12: 259266,
1994
Chazot C, Charra B, Laurent G, Didier C, Vo
Van C, Terrat JC, Calemard E, Vanel T,
Ruffet M: Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant 10: 831837, 1995
Agarwal R, Metiku T, Tegegne GG, Light
RP, Bunaye Z, Bekele DM, Kelley K: Diagnosing hypertension by intradialytic
blood pressure recordings. Clin J Am Soc
Nephrol 3: 13641372, 2008
Agarwal R: Role of home blood pressure
monitoring in hemodialysis patients. Am J
Kidney Dis 33: 682687, 1999
Agarwal R, Peixoto AJ, Santos SF, Zoccali C:
Out-of-ofce blood pressure monitoring in
chronic kidney disease. Blood Press Monit
14: 211, 2009
Pickering TG, Miller NH, Ogedegbe G,
Krakoff LR, Artinian NT, Goff D; American
Heart AssociationAmerican Society of HypertensionPreventive Cardiovascular Nurses
Association: Call to action on use and reimbursement for home blood pressure
monitoring: A joint scientic statement from
the American Heart Association, American
Society Of Hypertension, and Preventive
Cardiovascular Nurses Association. Hypertension 52: 1029, 2008
Parati G, Stergiou GS, Asmar R, Bilo G, de
Leeuw P, Imai Y, Kario K, Lurbe E, Manolis A,
Mengden T, OBrien E, Ohkubo T, Padeld
P, Palatini P, Pickering T, Redon J, Revera M,
Ruilope LM, Shennan A, Staessen JA, Tisler
A, Waeber B, Zanchetti A, Mancia G; ESH
Working Group on Blood Pressure Monitoring: European Society of Hypertension
guidelines for blood pressure monitoring at
home: A summary report of the Second International Consensus Conference on
Home Blood Pressure Monitoring. J Hypertens 26: 15051526, 2008
Agarwal R: Managing hypertension using
home blood pressure monitoring among
haemodialysis patientsa call to action.
1642
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
Nephrol Dial Transplant 25: 17661771,

2010
Agarwal R, Andersen MJ, Bishu K, Saha C:
Home blood pressure monitoring improves
the diagnosis of hypertension in hemodialysis patients. Kidney Int 69: 900906, 2006
Agarwal R, Satyan S, Alborzi P, Light RP,
Tegegne GG, Mazengia HS, Yigazu PM:
Home blood pressure measurements for
managing hypertension in hemodialysis
patients. Am J Nephrol 30: 126134, 2009
Agarwal R, Brim NJ, Mahenthiran J,
Andersen MJ, Saha C: Out-of-hemodialysisunit blood pressure is a superior determinant of left ventricular hypertrophy.
Hypertension 47: 6268, 2006
Moriya H, Ohtake T, Kobayashi S: Aortic
stiffness, left ventricular hypertrophy and
weekly averaged blood pressure (WAB) in
patients on haemodialysis. Nephrol Dial
Transplant 22: 11981204, 2007
Moriya H, Oka M, Maesato K, Mano T, Ikee
R, Ohtake T, Kobayashi S: Weekly averaged
blood pressure is more important than a
single-point blood pressure measurement
in the risk stratication of dialysis patients.
Clin J Am Soc Nephrol 3: 416422, 2008
Amar J, Vernier I, Rossignol E, Bongard V,
Arnaud C, Conte JJ, Salvador M,
Chamontin B: Nocturnal blood pressure
and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 57: 24852491, 2000
Alborzi P, Patel N, Agarwal R: Home blood
pressures are of greater prognostic value
than hemodialysis unit recordings. Clin J
Am Soc Nephrol 2: 12281234, 2007
Agarwal R: Hypervolemia is associated with
increased mortality among hemodialysis
da Silva GV, de Barros S, Abensur H, Ortega
KC, Mion D Jr; Cochrane Renal Group Prospective Trial Register: CRG060800146:
Home blood pressure monitoring in blood
pressure control among haemodialysis patients: An open randomized clinical trial.
2009
Kauric-Klein Z, Artinian N: Improving blood
pressure control in hypertensive hemodialysis patients. CANNT J 17: 2428, 3136,
quiz 2930, 3738, 2007
Agarwal R, Light RP: Chronobiology of arterial hypertension in hemodialysis patients: Implications for home blood
pressure monitoring. Am J Kidney Dis 54:
693701, 2009
Mitra S, Chandna SM, Farrington K: What is
hypertension in chronic haemodialysis? The
role of interdialytic blood pressure monitoring. Nephrol Dial Transplant 14: 2915
2921, 1999
Agarwal R, Andersen MJ, Light RP: Location
not quantity of blood pressure measurements predicts mortality in hemodialysis
61. Mansoor GA, White WB: Ambulatory blood

pressure monitoring is a useful clinical tool
in nephrology. Am J Kidney Dis 30: 591
605, 1997
62. Peixoto AJ, Santos SF, Mendes RB, Crowley
ST, Maldonado R, Orias M, Mansoor GA,
White WB: Reproducibility of ambulatory
blood pressure monitoring in hemodialysis
patients. Am J Kidney Dis 36: 983990,
2000
63. Townsend RR, Ford V: Ambulatory blood
pressure monitoring: Coming of age in nephrology. J Am Soc Nephrol 7: 22792287,
1996
64. Agarwal R: Blood pressure and mortality
among hemodialysis patients. Hypertension 55: 762768, 2010
65. Peixoto AJ, Gray TA, Crowley ST: Validation
of the SpaceLabs 90207 ambulatory blood
pressure device for hemodialysis patients.
Blood Press Monit 4: 217221, 1999
66. Agarwal R, Lewis RR: Prediction of hypertension in chronic hemodialysis patients.
Kidney Int 60: 19821989, 2001
67. Kelley K, Light RP, Agarwal R: Trended cosinor change model for analyzing hemodynamic rhythm patterns in hemodialysis
68. Agarwal R, Light RP: Arterial stiffness and
interdialytic weight gain inuence ambulatory blood pressure patterns in hemodialysis patients. Am J Physiol Renal Physiol 294:
F303F308, 2008
69. Ventura JE, Spsito M: Volume sensitivity of
blood pressure in end-stage renal disease.
Nephrol Dial Transplant 12: 485491, 1997
70. Inrig JK, Oddone EZ, Hasselblad V,
Gillespie B, Patel UD, Reddan D, Toto R,
Himmelfarb J, Winchester JF, Stivelman J,
Lindsay RM, Szczech LA: Association of intradialytic blood pressure changes with
hospitalization and mortality rates in prevalent ESRD patients. Kidney Int 71: 454
461, 2007
71. Inrig JK, Patel UD, Toto RD, Szczech LA:
Association of blood pressure increases
during hemodialysis with 2-year mortality in
incident hemodialysis patients: A secondary analysis of the Dialysis Morbidity and
Mortality Wave 2 Study. Am J Kidney Dis
54: 881890, 2009
72. Inrig JK: Intradialytic hypertension: A lessrecognized cardiovascular complication of
hemodialysis. Am J Kidney Dis 55: 580
589, 2010
73. Chou KJ, Lee PT, Chen CL, Chiou CW, Hsu
CY, Chung HM, Liu CP, Fang HC: Physiological changes during hemodialysis in patients with intradialysis hypertension.
Kidney Int 69: 18331838, 2006
74. Agarwal R, Light RP: Intradialytic hypertension is a marker of volume excess. Nephrol
Dial Transplant 25: 33553361, 2010
75. Van Buren PN, Kim C, Toto R, Inrig JK:
Intradialytic hypertension and the association with interdialytic ambulatory blood
J Am Soc Nephrol 25: 16301646, 2014
www.jasn.org
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
pressure. Clin J Am Soc Nephrol 6: 1684

1691, 2011
Cirit M, Akiek F, Terzio
glu E, Soydasx C, Ok
E, Ozbasxli CF, Basxi A, Mees EJ: Paradoxical rise in blood pressure during ultraltration in dialysis patients. Nephrol Dial
Transplant 10: 14171420, 1995
Agarwal R, Alborzi P, Satyan S, Light RP:
Dry-weight reduction in hypertensive hemodialysis patients (DRIP): A randomized,
controlled trial. Hypertension 53: 500507,
2009
Inrig JK, Van Buren P, Kim C, Vongpatanasin
W, Povsic TJ, Toto R: Probing the mechanisms of intradialytic hypertension: A pilot
study targeting endothelial cell dysfunction. Clin J Am Soc Nephrol 7: 13001309,
2012
Miller BW, Cress CL, Johnson ME, Nichols
DH, Schnitzler MA: Exercise during hemodialysis decreases the use of antihypertensive medications. Am J Kidney Dis 39:
828833, 2002
Kooman JP, van der Sande F, Leunissen K,
Locatelli F: Sodium balance in hemodialysis
therapy. Semin Dial 16: 351355, 2003
Krautzig S, Janssen U, Koch KM,
Granolleras C, Shaldon S: Dietary salt restriction and reduction of dialysate sodium
to control hypertension in maintenance
haemodialysis patients. Nephrol Dial
Transplant 13: 552553, 1998
Tomson CR: Advising dialysis patients to
restrict uid intake without restricting sodium intake is not based on evidence and
is a waste of time. Nephrol Dial Transplant
16: 15381542, 2001
Bibbins-Domingo K, Chertow GM, Coxson
PG, Moran A, Lightwood JM, Pletcher MJ,
Goldman L: Projected effect of dietary salt
reductions on future cardiovascular disease.
N Engl J Med 362: 590599, 2010
Ozkahya M, Toz H, Qzerkan F, Duman S, Ok
E, Basci A, Mees EJ: Impact of volume
control on left ventricular hypertrophy in
dialysis patients. J Nephrol 15: 655660,
2002
Ogden DA: A double blind crossover comparison of high and low sodium dialysis.
Proc Clin Dial Transplant Forum 8: 157
165, 1978
Cybulsky AV, Matni A, Hollomby DJ: Effects
of high sodium dialysate during maintenance hemodialysis. Nephron 41: 5761,
1985
Daugirdas JT, Al-Kudsi RR, Ing TS, Norusis
MJ: A double-blind evaluation of sodium
gradient hemodialysis. Am J Nephrol 5:
163168, 1985
Barr PE, Brunelle G, Gascon-Barr M: A
randomized double blind trial of dialysate
sodiums of 145 mEq/L, 150 mEq/L, and 155
mEq/L. ASAIO Trans 34: 338341, 1988
Munoz Mendoza J, Sun S, Chertow GM,
Moran J, Doss S, Schiller B: Dialysate sodium and sodium gradient in maintenance
J Am Soc Nephrol 25: 16301646, 2014
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
hemodialysis: A neglected sodium restriction approach? Nephrol Dial Transplant 26: 12811287, 2011
Flanigan M: Dialysate composition and hemodialysis hypertension. Semin Dial 17:
279283, 2004
Santos SF, Peixoto AJ: Revisiting the dialysate sodium prescription as a tool for
better blood pressure and interdialytic
weight gain management in hemodialysis
patients. Clin J Am Soc Nephrol 3: 522
530, 2008
de Paula FM, Peixoto AJ, Pinto LV, Dorigo
D, Patricio PJ, Santos SF: Clinical consequences of an individualized dialysate
sodium prescription in hemodialysis patients. Kidney Int 66: 12321238, 2004
Manlucu J, Gallo K, Heidenheim PA,
Lindsay RM: Lowering postdialysis plasma
sodium (conductivity) to increase sodium
removal in volume-expanded hemodialysis
patients: A pilot study using a biofeedback
software system. Am J Kidney Dis 56: 69
76, 2010
Sang GL, Kovithavongs C, Ulan R,
Kjellstrand CM: Sodium ramping in hemodialysis: A study of benecial and adverse
effects. Am J Kidney Dis 29: 669677, 1997
Song JH, Lee SW, Suh CK, Kim MJ: Timeaveraged concentration of dialysate sodium
relates with sodium load and interdialytic
weight gain during sodium-proling hemodialysis. Am J Kidney Dis 40: 291301,
2002
Davies S, Carlsson O, Simonsen O,
Johansson AC, Venturoli D, Ledebo I,
Wieslander A, Chan C, Rippe B: The effects
of low-sodium peritoneal dialysis uids on
blood pressure, thirst and volume status.
2009
Stewart WK, Fleming LW: Blood pressure
control during maintenance haemodialysis
with isonatric (high sodium) dialysate.
Postgrad Med J 50: 260264, 1974
Sinha AD, Agarwal R: Can chronic volume
overload be recognized and prevented in
hemodialysis patients? The pitfalls of the
clinical examination in assessing volume
status. Semin Dial 22: 480482, 2009
Agarwal R, Andersen MJ, Pratt JH: On the
importance of pedal edema in hemodialysis
patients. Clin J Am Soc Nephrol 3: 153
158, 2008
Bridges N, Jarquin-Valdivia AA: Use of the
Trendelenburg position as the resuscitation
position: To T or not to T? Am J Crit Care 14:
364368, 2005
Monnet X, Teboul JL: Passive leg raising.
Intensive Care Med 34: 659663, 2008
Vertes V, Cangiano JL, Berman LB, Gould A:
Hypertension in end-stage renal disease. N
Engl J Med 280: 978981, 1969
Kayikcioglu M, Tumuklu M, Ozkahya M,
Ozdogan O, Asci G, Duman S, Toz H, Can
LH, Basci A, Ok E: The benet of salt
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
BRIEF REVIEW
restriction in the treatment of end-stage

renal disease by haemodialysis. Nephrol
Goldstein SL, Smith CM, Currier H: Noninvasive interventions to decrease hospitalization and associated costs for pediatric
patients receiving hemodialysis. J Am Soc
Nephrol 14: 21272131, 2003
Rodriguez HJ, Domenici R, Diroll A,
Goykhman I: Assessment of dry weight by
monitoring changes in blood volume during hemodialysis using Crit-Line. Kidney Int
68: 854861, 2005
Patel HP, Goldstein SL, Mahan JD, Smith B,
Fried CB, Currier H, Flynn JT: A standard,
noninvasive monitoring of hematocrit algorithm improves blood pressure control in
pediatric hemodialysis patients. Clin J Am
Soc Nephrol 2: 252257, 2007
Reddan DN, Szczech LA, Hasselblad V,
Lowrie EG, Lindsay RM, Himmelfarb J, Toto
RD, Stivelman J, Winchester JF, Zillman LA,
Califf RM, Owen WF Jr: Intradialytic blood
volume monitoring in ambulatory hemodialysis patients: A randomized trial. J Am Soc
Nephrol 16: 21622169, 2005
Wizemann V, Wabel P, Chamney P, Zaluska
W, Moissl U, Rode C, Malecka-Masalska T,
Marcelli D: The mortality risk of overhydration in haemodialysis patients.
2009
Inrig JK, Patel UD, Toto RD, Reddan DN,
Himmelfarb J, Lindsay RM, Stivelman J,
Winchester JF, Szczech LA: Decreased
pulse pressure during hemodialysis is associated with improved 6-month outcomes.
Kidney Int 76: 10981107, 2009
Shoji T, Tsubakihara Y, Fujii M, Imai E:
Hemodialysis-associated hypotension as an
independent risk factor for two-year mortality
in hemodialysis patients. Kidney Int 66:
12121220, 2004
Tattersall J, Martin-Malo A, Pedrini L, Basci
A, Canaud B, Fouque D, Haage P, Konner K,
Kooman J, Pizzarelli F, Tordoir J,
Vennegoor M, Wanner C, ter Wee P,
Vanholder R: EBPG guideline on dialysis
strategies. Nephrol Dial Transplant 22
[Suppl 2]: ii5ii21, 2007
Foley RN, Gilbertson DT, Murray T, Collins
AJ: Long interdialytic interval and mortality
among patients receiving hemodialysis. N
Engl J Med 365: 10991107, 2011
Charra B, Calemard E, Ruffet M, Chazot C,
Terrat J-C, Vanel T, Laurent G: Survival as an
index of adequacy of dialysis. Kidney Int 41:
12861291, 1992
Brunet P, Saingra Y, Leonetti F, VacherCoponat H, Ramananarivo P, Berland Y:
Tolerance of haemodialysis: A randomized
cross-over trial of 5-h versus 4-h treatment
time. Nephrol Dial Transplant 11[Suppl 8]:
4651, 1996
Chan CT, Floras JS, Miller JA, Richardson
RM, Pierratos A: Regression of left
1643
BRIEF REVIEW
116.
117.
118.
119.
120.
121.
122.
123.
www.jasn.org
ventricular hypertrophy after conversion to

nocturnal hemodialysis. Kidney Int 61:
22352239, 2002
Woods JD, Port FK, Orzol S, Buoncristiani
U, Young E, Wolfe RA, Held PJ: Clinical and
biochemical correlates of starting daily
hemodialysis. Kidney Int 55: 24672476,
1999
Beecroft JM, Hoffstein V, Pierratos A, Chan
CT, McFarlane P, Hanly PJ: Nocturnal haemodialysis increases pharyngeal size in patients with sleep apnoea and end-stage
renal disease. Nephrol Dial Transplant 23:
673679, 2008
Chan CT, Jain V, Picton P, Pierratos A,
Floras JS: Nocturnal hemodialysis increases
arterial baroreex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal
disease. Kidney Int 68: 338344, 2005
Saad E, Charra B, Raj DS: Hypertension
control with daily dialysis. Semin Dial 17:
295298, 2004
Culleton BF, Walsh M, Klarenbach SW,
Mortis G, Scott-Douglas N, Quinn RR,
Tonelli M, Donnelly S, Friedrich MG, Kumar
A, Mahallati H, Hemmelgarn BR, Manns BJ:
Effect of frequent nocturnal hemodialysis vs
conventional hemodialysis on left ventricular mass and quality of life: A randomized
controlled trial. JAMA 298: 12911299,
2007
Chertow GM, Levin NW, Beck GJ, Depner
TA, Eggers PW, Gassman JJ, Gorodetskaya
I, Greene T, James S, Larive B, Lindsay RM,
Mehta RL, Miller B, Ornt DB, Rajagopalan S,
Rastogi A, Rocco MV, Schiller B, Sergeyeva
O, Schulman G, Ting GO, Unruh ML, Star
RA, Kliger AS; FHN Trial Group: In-center
hemodialysis six times per week versus
three times per week. N Engl J Med 363:
22872300, 2010
Agarwal R: Frequent versus standard hemodialysis. N Engl J Med 364: 975976,
author reply 976, 2011
Rocco MV, Lockridge RS Jr, Beck GJ,
Eggers PW, Gassman JJ, Greene T, Larive
B, Chan CT, Chertow GM, Copland M, Hoy
CD, Lindsay RM, Levin NW, Ornt DB,
Pierratos A, Pipkin MF, Rajagopalan S,
Stokes JB, Unruh ML, Star RA, Kliger AS,
Kliger A, Eggers P, Briggs J, Hostetter T,
Narva A, Star R, Augustine B, Mohr P, Beck
G, Fu Z, Gassman J, Greene T, Daugirdas J,
Hunsicker L, Larive B, Li M, Mackrell J,
Wiggins K, Sherer S, Weiss B, Rajagopalan
S, Sanz J, Dellagrottaglie S, Kariisa M, Tran
T, West J, Unruh M, Keene R, Schlarb J,
Chan C, McGrath-Chong M, Frome R,
Higgins H, Ke S, Mandaci O, Owens C, Snell
C, Eknoyan G, Appel L, Cheung A, Derse A,
Kramer C, Geller N, Grimm R, Henderson L,
Prichard S, Roecker E, Rocco M, Miller B,
Riley J, Schuessler R, Lockridge R, Pipkin M,
Peterson C, Hoy C, Fensterer A,
Steigerwald D, Stokes J, Somers D, Hilkin A,
1644
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
Lilli K, Wallace W, Franzwa B, Waterman E,

Chan C, McGrath-Chong M, Copland M,
Levin A, Sioson L, Cabezon E, Kwan S,
Roger D, Lindsay R, Suri R, Champagne J,
Bullas R, Garg A, Mazzorato A, Spanner E,
Rocco M, Burkart J, Moossavi S, Mauck V,
Kaufman T, Pierratos A, Chan W, Regozo K,
Kwok S; Frequent Hemodialysis Network
(FHN) Trial Group: The effects of frequent
nocturnal home hemodialysis: The Frequent Hemodialysis Network Nocturnal
Trial. Kidney Int 80: 10801091, 2011
Twardowski ZJ: Treatment time and ultraltration rate are more important in dialysis
prescription than small molecule clearance.
Blood Purif 25: 9098, 2007
Katzarski KS, Charra B, Luik AJ, Nisell J,
Divino Filho JC, Leypoldt JK, Leunissen
KM, Laurent G, Bergstrm J: Fluid state and
blood pressure control in patients treated
with long and short haemodialysis. Nephrol
Agarwal R, Bouldin JM, Light RP, Garg A:
Probing dry-weight improves left ventricular mass index. Am J Nephrol 33: 373380,
2011
Hrl MP, Hrl WH: Drug therapy for hypertension in hemodialysis patients. Semin
Dial 17: 288294, 2004
Hayashi SY, Seeberger A, Lind B, Gunnes S,
Alvestrand A, do Nascimento MM, Lindholm
B, Brodin LA: Acute effects of low and high
intravenous doses of furosemide on myocardial function in anuric haemodialysis patients:
A tissue Doppler study. Nephrol Dial Transplant 23: 13551361, 2008
Hoyer J, Schulte KL, Lenz T: Clinical pharmacokinetics of angiotensin converting
enzyme (ACE) inhibitors in renal failure. Clin
Pharmacokinet 24: 230254, 1993
Agarwal R, Weir MR: Dry-weight: A concept
revisited in an effort to avoid medicationdirected approaches for blood pressure
control in hemodialysis patients. Clin J Am
Soc Nephrol 5: 12551260, 2010
Zannad F, Kessler M, Lehert P, Grnfeld
JP, Thuilliez C, Leizorovicz A, Lechat P:
Prevention of cardiovascular events in endstage renal disease: Results of a randomized
trial of fosinopril and implications for future studies. Kidney Int 70: 13181324,
2006
Takahashi A, Takase H, Toriyama T, Sugiura
T, Kurita Y, Ueda R, Dohi Y: Candesartan, an
angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on
chronic haemodialysisa randomized
study. Nephrol Dial Transplant 21: 2507
2512, 2006
Cice G, Ferrara L, DAndrea A, DIsa S, Di
Benedetto A, Cittadini A, Russo PE, Golino
P, Calabr R: Carvedilol increases two-year
survivalin dialysis patients with dilated
cardiomyopathy: A prospective, placebocontrolled trial. J Am Coll Cardiol 41: 1438
1444, 2003
134. Heerspink HJ, Ninomiya T, Zoungas S, de

Zeeuw D, Grobbee DE, Jardine MJ,
Gallagher M, Roberts MA, Cass A, Neal B,
Perkovic V: Effect of lowering blood pressure on cardiovascular events and mortality
in patients on dialysis: A systematic review
and meta-analysis of randomised controlled trials. Lancet 373: 10091015, 2009
135. Agarwal R, Sinha AD: Cardiovascular protection with antihypertensive drugs in dialysis
patients: Systematic review and meta-analysis.
Hypertension 53: 860866, 2009
136. Agarwal R, Sinha AD, Pappas MK, Abraham
TN, Tegegne GG: Hypertension in hemodialysis treated with atenolol or lisinopril: A
randomized controlled trial. Nephrol Dial
Transplant 29: 672681, 2014
137. Buckner FS, Eschbach JW, Haley NR,
Davidson RC, Adamson JW: Hypertension
following erythropoietin therapy in anemic
hemodialysis patients. Am J Hypertens 3:
947955, 1990
138. Eschbach JW, Kelly MR, Haley NR, Abels RI,
Adamson JW: Treatment of the anemia of
progressive renal failure with recombinant
human erythropoietin. N Engl J Med 321:
158163, 1989
139. Eschbach JW, Abdulhadi MH, Browne JK,
Delano BG, Downing MR, Egrie JC, Evans
RW, Friedman EA, Graber SE, Haley NR,
Korbet S, Krantz SB, Lundin AP, Nissenson
AR, Ogden DA, Paganini EP, Rader B,
Rutsky EA, Stivelman J, Stone WJ, Teschan
P, Van Stone JC, Van Wyck DB, Zuckerman
K, Adamson JW: Recombinant human
erythropoietin in anemic patients with endstage renal disease. Results of a phase III
multicenter clinical trial. Ann Intern Med
111: 9921000, 1989
140. Abraham PA, Macres MG: Blood pressure in
hemodialysis patients during amelioration
of anemia with erythropoietin. J Am Soc
Nephrol 2: 927936, 1991
141. Kaupke CJ, Kim S, Vaziri ND: Effect of
erythrocyte mass on arterial blood pressure
in dialysis patients receiving maintenance
erythropoietin therapy. J Am Soc Nephrol
4: 18741878, 1994
142. Lebel M, Kingma I, Grose JH, Langlois S:
Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis
patients. J Am Soc Nephrol 9: 97104, 1998
143. Wang XQ, Vaziri ND: Erythropoietin depresses nitric oxide synthase expression by
human endothelial cells. Hypertension 33:
894899, 1999
144. Bode-Bger SM, Bger RH, Kuhn M,
Radermacher J, Frlich JC: Recombinant
human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor
prostanoids. Kidney Int 50: 12551261, 1996
145. Carlini R, Obialo CI, Rothstein M: Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and
blood pressure in hemodialysis patients.
Am J Hypertens 6: 103107, 1993
J Am Soc Nephrol 25: 16301646, 2014
www.jasn.org
146. Carlini RG, Dusso AS, Obialo CI, Alvarez

UM, Rothstein M: Recombinant human
erythropoietin (rHuEPO) increases endothelin1 release by endothelial cells. Kidney Int 43:
10101014, 1993
147. Eggena P, Willsey P, Jamgotchian N,
Truckenbrod L, Hu MS, Barrett JD, Eggena
MP, Clegg K, Nakhoul F, Lee DB: Inuence
of recombinant human erythropoietin on
blood pressure and tissue renin-angiotensin
systems. Am J Physiol 261: E642E646,
1991
148. Hand MF, Haynes WG, Johnstone HA,
Anderton JL, Webb DJ: Erythropoietin
enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 48:
806813, 1995
149. Amar J, Vernier I, Rossignol E, Lenfant V,
Conte JJ, Chamontin B: Inuence of nycthemeral blood pressure pattern in treated
hypertensive patients on hemodialysis.
Kidney Int 51: 18631866, 1997
150. Canadian Erythropoietin Study Group: Effect of recombinant human erythropoietin
therapy on blood pressure in hemodialysis
151. Lebel M, Kingma I, Grose JH, Langlois S:
Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in
normotensive and in untreated borderline
hypertensive hemodialysis patients. Am J
Hypertens 8: 545551, 1995
152. Ishimitsu T, Tsukada H, Ogawa Y, Numabe
A, Yagi S: Genetic predisposition to hypertension facilitates blood pressure elevation
in hemodialysis patients treated with
erythropoietin. Am J Med 94: 401406,
1993
153. Zoccali C, Benedetto FA, Tripepi G,
Cambareri F, Panuccio V, Candela V,
Mallamaci F, Enia G, Labate C, Tassone F:
Nocturnal hypoxemia, night-day arterial
pressure changes and left ventricular geometry in dialysis patients. Kidney Int 53:
10781084, 1998
154. Unruh ML, Sanders MH, Redline S, Piraino
BM, Umans JG, Hammond TC, Sharief I,
Punjabi NM, Newman AB: Sleep apnea in
patients on conventional thrice-weekly
hemodialysis: Comparison with matched
controls from the Sleep Heart Health
Study. J Am Soc Nephrol 17: 35033509,
2006
155. Abdel-Kader K, Dohar S, Shah N, Jhamb M,
Reis SE, Strollo P, Buysse D, Unruh ML:
Resistant hypertension and obstructive
sleep apnea in the setting of kidney disease. J Hypertens 30: 960966, 2012
156. Park J, Campese VM: Resistant hypertension
and obstructive sleep apnea in end-stage
renal disease. J Hypertens 30: 880881,
2012
157. Tada T, Kusano KF, Ogawa A, Iwasaki J,
Sakuragi S, Kusano I, Takatsu S, Miyazaki M,
Ohe T: The predictors of central and obstructive sleep apnoea in haemodialysis
J Am Soc Nephrol 25: 16301646, 2014
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
patients. Nephrol Dial Transplant 22: 1190

1197, 2007
Dorhout Mees EJ: Hypertension in haemodialysis patients: Who cares? Nephrol Dial
Transplant 14: 2830, 1999
Duranti E, Imperiali P, Sasdelli M: Is
hypertension a mortality risk factor in dialysis? Kidney Int Suppl 55: S173S174,
1996
Fleischmann EH, Bower JD, Salahudeen
AK: Are conventional cardiovascular risk
factors predictive of two-year mortality in
hemodialysis patients? Clin Nephrol 56:
221230, 2001
Foley RN, Parfrey PS, Harnett JD, Kent GM,
Murray DC, Barre PE: Impact of hypertension on cardiomyopathy, morbidity and
mortality in end-stage renal disease. Kidney
Int 49: 13791385, 1996
Kalantar-Zadeh K, Kilpatrick RD, McAllister
CJ, Greenland S, Kopple JD: Reverse epidemiology of hypertension and cardiovascular death in hemodialysis patients: The
58th annual fall conference and scientic
sessions.. Hypertension 45: 811817, 2005
Mazzuchi N, Carbonell E, Fernndez-Cean
J: Importance of blood pressure control in
hemodialysis patient survival. Kidney Int 58:
21472154, 2000
Salem MM, Bower J: Hypertension in the
hemodialysis population: Any relation to
one-year survival? Am J Kidney Dis 28: 737
740, 1996
Kawamura M, Fijimoto S, Hisanaga S,
Yamamoto Y, Eto T: Incidence, outcome,
and risk factors of cerebrovascular events in
patients undergoing maintenance hemodialysis. Am J Kidney Dis 31: 991996, 1998
van der Sande FM, Hermans MM, Leunissen
KM, Kooman JP: Noncardiac consequences
of hypertension in hemodialysis patients.
Semin Dial 17: 304306, 2004
Savazzi GM, Cusmano F, Bergamaschi E,
Vinci S, Allegri L, Garini G: Hypertension as
an etiopathological factor in the development of cerebral atrophy in hemodialyzed patients. Nephron 81: 1724, 1999
Takeda A, Toda T, Fujii T, Shinohara S,
Sasaki S, Matsui N: Discordance of inuence of hypertension on mortality and
cardiovascular risk in hemodialysis patients.
Am J Kidney Dis 45: 112118, 2005
De Lima JJ, Lopes HF, Grupi CJ, Abensur H,
Giorgi MC, Krieger EM, Pileggi F: Blood
pressure inuences the occurrence of
complex ventricular arrhythmia in hemodialysis patients. Hypertension 26: 1200
1203, 1995
Tomita J, Kimura G, Inoue T, Inenaga T,
Sanai T, Kawano Y, Nakamura S, Baba S,
Matsuoka H, Omae T: Role of systolic blood
pressure in determining prognosis of hemodialyzed patients. Am J Kidney Dis 25:
405412, 1995
Port FK, Hulbert-Shearon TE, Wolfe RA,
Bloembergen WE, Golper TA, Agodoa LY,
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
BRIEF REVIEW
Young EW: Predialysis blood pressure and

mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33: 507517, 1999
Salem MM: Hypertension in the haemodialysis population: Any relationship to
2-years survival? Nephrol Dial Transplant
14: 125128, 1999
Zager PG, Nikolic J, Brown RH, Campbell
MA, Hunt WC, Peterson D, Van Stone J,
Levey A, Meyer KB, Klag MJ, Johnson HK,
Clark E, Sadler JH, Teredesai P: U curve
association of blood pressure and mortality
in hemodialysis patients. Medical Directors
of Dialysis Clinic, Inc. Kidney Int 54: 561
569, 1998
Lacson E Jr, Lazarus JM: The association
between blood pressure and mortality in
ESRD-not different from the general population? Semin Dial 20: 510517, 2007
Li Z, Lacson E Jr, Lowrie EG, Ofsthun NJ,
Kuhlmann MK, Lazarus JM, Levin NW: The
epidemiology of systolic blood pressure
and death risk in hemodialysis patients. Am
J Kidney Dis 48: 606615, 2006
Charra B: Control of blood pressure in long
slow hemodialysis. Blood Purif 12: 252
258, 1994
Stidley CA, Hunt WC, Tentori F, Schmidt D,
Rohrscheib M, Paine S, Bedrick EJ, Meyer
KB, Johnson HK, Zager PG; Medical Directors of Dialysis Clinic Inc: Changing relationship of blood pressure with mortality
over time among hemodialysis patients. J
Am Soc Nephrol 17: 513520, 2006
Degoulet P, Legrain M, Rach I, Aim F,
Devris C, Rojas P, Jacobs C: Mortality risk
factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 31: 103110, 1982
Groothoff J, Gruppen M, de Groot E,
Offringa M: Cardiovascular disease as a late
complication of end-stage renal disease in
children. Perit Dial Int 25[Suppl 3]: S123
S126, 2005
Parekh RS, Carroll CE, Wolfe RA, Port FK:
Cardiovascular mortality in children and
young adults with end-stage kidney disease. J Pediatr 141: 191197, 2002
Mitsnefes M, Stablein D: Hypertension in
pediatric patients on long-term dialysis:
a report of the North American Pediatric Renal Transplant Cooperative Study
(NAPRTCS). Am J Kidney Dis 45: 309315,
2005
Halbach SM, Martz K, Mattoo T, Flynn J:
Predictors of blood pressure and its control
in pediatric patients receiving dialysis. J
Pediatr 160: 621625, e1, 2012
Kramer AM, van Stralen KJ, Jager KJ,
Schaefer F, Verrina E, Seeman T, Lewis MA,
Boehm M, Simonetti GD, Novljan G,
Groothoff JW: Demographics of blood
pressure and hypertension in children on
renal replacement therapy in Europe. Kidney Int 80: 10921098, 2011
1645
BRIEF REVIEW
www.jasn.org
184. Mitsnefes MM, Daniels SR, Schwartz SM,

Khoury P, Strife CF: Changes in left ventricular mass in children and adolescents
during chronic dialysis. Pediatr Nephrol 16:
318323, 2001
185. Bakkaloglu SA, Borzych D, Soo Ha I,
Serdaroglu E, Bscher R, Salas P, Patel H,
Drozdz D, Vondrak K, Watanabe A, Villagra J,
Yavascan O, Valenzuela M, Gipson D, Ng KH,
Warady BA, Schaefer F; International Pediatric
Peritoneal Dialysis Network: Cardiac geometry
in children receiving chronic peritoneal dialysis: Findings from the International Pediatric
Peritoneal Dialysis Network (IPPN) registry.
Clin J Am Soc Nephrol 6: 19261933, 2011
186. Mitsnefes MM, Daniels SR, Schwartz SM,
Meyer RA, Khoury P, Strife CF: Severe left
ventricular hypertrophy in pediatric dialysis:
1646
Prevalence and predictors. Pediatr Nephrol

14: 898902, 2000
187. Hltt T, Happonen JM, Rnnholm K,
Fyhrquist F, Holmberg C: Hypertension,
cardiac state, and the role of volume overload during peritoneal dialysis. Pediatr
Nephrol 16: 324331, 2001
188. Schrer K, Schmidt KG, Soergel M: Cardiac
function and structure in patients with
chronic renal failure. Pediatr Nephrol 13:
951965, 1999
189. National High Blood Pressure Education
Program Working Group on High Blood
Pressure in Children and Adolescents: The
fourth report on the diagnosis, evaluation,
and treatment of high blood pressure in
children and adolescents. Pediatrics 114
[Suppl 4th Report]: 555576, 2004
190. Kidney Disease Outcomes Quality Initiative

(K/DOQI): K/DOQI clinical practice guidelines on hypertension and antihypertensive
agents in chronic kidney disease. Am J
Kidney Dis 43[Suppl 1]: S1S290, 2004
191. Ulinski T, Genty J, Viau C, Tillous-Borde I,
Deschnes G: Reduction of left ventricular
hypertrophy in children undergoing hemodialysis. Pediatr Nephrol 21: 11711178, 2006
192. Thalange NK, Foster PJ, Gill MS, Price DA,
Clayton PE: Model of normal prepubertal
growth. Arch Dis Child 75: 427431, 1996
193. Paglialonga F, Ardissino G, Galli MA,
Scara RV, Testa S, Edefonti A: Bioimpedance analysis and cardiovascular
status in pediatric patients on chronic hemodialysis. Hemodial Int 16[Suppl 1]: S20
S25, 2012
J Am Soc Nephrol 25: 16301646, 2014

1630 Full

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

1630 Full

Uploaded by

Copyright:

Available Formats

BRIEF REVIEW

Assessment and Management of Hypertension in

Hypertension is common among patients with ESRD. In this review, we

The prevalence, treatment, and control

Epidemiology with Routine BP

The prevalence of hypertension (dened

antihypertensive drug use per se do not

The prevalence of hypertension (dened

Published online ahead of print. Publication date

J Am Soc Nephrol 25: 16301646, 2014

Some studies suggest that hypertension

The diagnosis of hypertension among

may lead to overtreatment or undertreatment of hypertension.1922 Diagnosing

targets had more intradialytic hypotension.35 What is clear is that interdialytic

events52 or mortality.5255 The association

standard for diagnosing hypertension.27,6163 Compared with peridialytic

Journal of the American Society of Nephrology

seven hypertensive patients on HD with

Once an accurate diagnosis is made, the

dialysis. These principles are further discussed.

J Am Soc Nephrol 25: 16301646, 2014

High sodium dialysis was initially prescribed to provide hemodynamic stability,

Table 1. Diagnosis and epidemiology

thirst, increased interdialytic weight gain,

The management of dry weight poses

Journal of the American Society of Nephrology

0.20.3 kg in an adult) either without

Turkey, Kayikcioglu et al. compared the

salt restriction and dry weight reduction

Dry Weight and Outcomes

respectively. An elaborate protocol was

and a lower ECF volume state, and may

The European Best Practice Guidelines

Journal of the American Society of Nephrology

antihypertensive drugs, and excellent

FREQUENT DIALYSIS AND ITS

Observational studies suggest that conversion of patients from three times a

All classes of antihypertensive drugs,

hypertension in HD patients.127 Diuretics are generally ineffective at very low

in cardiovascular events with active treatment versus placebo.132 These conicting

An increase in BP is a well recognized

response to the effect of various vasoactive substances. 142,143 Several studies

Journal of the American Society of Nephrology

provoke intense sympathetic arousal and

Among HD patients, the relationship of BP

Table 2. Management of hypertension

relationship between BP and mortality.170,176 Consideration of the patient

Young adults with childhood-onset ESRD

pediatric ESRD. Hypertension was present in 69.4% of HD patients (using BP

National High Blood Pressure Education

Journal of the American Society of Nephrology

group of pediatric HD patients was associated with fewer episodes of pulmonary

J Am Soc Nephrol 25: 16301646, 2014

J Am Soc Nephrol 25: 16301646, 2014

dialysis: Results of an Italian multicentre

measurements in hemodialysis patients.

Akiba T: Prevalence and determinants of

Nephrol Dial Transplant 25: 17661771,

Journal of the American Society of Nephrology

61. Mansoor GA, White WB: Ambulatory blood

J Am Soc Nephrol 25: 16301646, 2014

pressure. Clin J Am Soc Nephrol 6: 1684

J Am Soc Nephrol 25: 16301646, 2014